4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
HBM Holdings Limited (2142) operates in the Biotechnology industry and is headquartered in Suzhou, China with about 272 employees. Its market capitalization is roughly $13 billion. In the fiscal year ended 2025-12-31, 2142 reported $158M in revenue and $91M in net income.
HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $158M | $38M | $90M | $41M |
| Gross Profit | $149M | $34M | $88M | $40M |
| Operating Income (EBIT) | $82M | ($2M) | $23M | ($121M) |
| Net Income | $91M | $3M | $23M | ($137M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $500M | $215M | $228M | $232M | — |
| Total Liabilities | $133M | $91M | $109M | $140M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2142 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms